Pharmacogenetics of asthma

European Respiratory Journal

Volumn 15, Issue 3, 2000, Pages 449-451

  Hall, I P ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ASTHMA; DISEASE SEVERITY; DNA POLYMORPHISM; GENE TARGETING; HEREDITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TANDEM REPEAT;

ASTHMA; HUMANS; PHARMACOGENETICS;

EID: 0034017468     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.2000.15.04.x     Document Type: Review

References (22)

1. Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 1997; 52: 1034-1040.
2. Dalen P, Dahl M-L, Bernai Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0,1,2,3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 444-452.
3. Pianeza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature 1998; 393: 750.
4. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342-349.
5. Halusdka MK, Fan J-B, Bentley K, et al. Patterns of single nucleotide polymorphisms in candidate genes for blood pressure homeostasis. Nature Genetics 1999; 22: 239-247.
6. 2 adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8: 334-339.
7. 2-AR) polymorphism determines susceptibility to bronchodilator desensitisation in asthmatics. Lancet 1997; 4: 995-999.
8. 2 adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly 16 correlates with the nocturnal phenotype. J Clin Invest 1995; 95: 1635-1641.
9. 2 adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp All 1998; 28: 442-448.
10. 2 agonist therapy in asthma. Eur Respir J 1998; 11: 589-593.
11. Dewar JC, Hall IP. A novel degenerate polymorphism in the human histamine H1 receptor gene. Am J Respir Crit Care Med 1998; 157: A773.
12. In KH, Asano K, Beler D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99: 1130-1137.
13. Lane SJ, Arm JP, Staynov DZ, Lee TH. Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma. Am J Respir Cell Mol Biol 1994; 11: 42-44.
14. 2 receptor gene in Maltese asthmatic patients. Br J Pharmacol 1999; 128: 121P.
15. 2-receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993; 268: 23116-23121.
16. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochem (USA) 1994; 33: 9414-9419.
17. 2 adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100: 3184-3188.
18. 2-adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med 1998; 158: 787-791.
19. The British Guidelines for Asthma Management: 1995 Review and Position Statement. Thorax 1997; 52 (Suppl. 1): S1-S21.
20. Drazen JM, Israel E, Obyrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197-206.
21. Drazen JM, Yandava CN, Dube L, et al. Phamacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genetics 1999; 22: 168-170.
22. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforrns. Physiol Rev 1995; 75: 725-748.